ACell, Inc. Names Patrick McBrayer Chief Executive Officer

Columbia, MD - (January 11, 2016) – ACell, Inc. today announced that it has named Patrick (Pat) McBrayer President and Chief Executive Officer. McBrayer succeeds Kyle Kerbawy, who will remain as Chairman of the Board.

McBrayer has more than 20 years of healthcare senior management experience. He currently serves on the Board of Directors of Misonix, Inc. and was President and CEO of AxioMed Spine Corporation until the company was acquired in 2014.

"Pat has strong executive experience in regulated healthcare environments, a track record of maximizing the potential of early-stage technology, and a proven commitment to improving patient care," said Kerbawy. "The Board is confident that he will be a transformational CEO for ACell as he leads our next phase of growth and innovation."

"ACell's pioneering technology has immense potential to help people in a wide range of therapeutic areas," said McBrayer. "I am honored to assume this leadership role, and look forward to working with our Board of Directors, management, and employee teams to advance ACell's current strategic priorities and develop new opportunities for growth."

About Patrick McBrayer

McBrayer is on the Board of Directors of Misonix Inc (NASDAQ:MSON), which markets therapeutic ultrasound medical devices world-wide. He has recently advised medical device companies in spine, orthopedics and biotechnology. McBrayer was President and Chief Executive Officer of AxioMed Spine Corporation until the company was acquired in 2014. AxioMed focused on restoring the native function of the spine with the company's Freedom total disc spine technology.

Prior to AxioMed, McBrayer was Chief Executive Officer of Xylos Corporation, a medical biomaterials company. He was also a Founder of Transave Inc. (now Insmed Inc.), a biotechnology company focused on the site specific treatment of lung disease. Prior to joining Xylos, McBrayer served as President and CEO of Exogen, Inc., a company focused on the non-invasive treatment of musculoskeletal injury and disease, which was acquired by Smith & Nephew, Inc. in 1999. Previously, McBrayer was President and CEO of Osteotech, Inc., a worldwide leader in tissue technology (acquired by Medtronic Inc). He has been responsible for a number of private placements, as well as Osteotech and Exogen's public offerings. He received the Thomas Alva Edison Patent Award in 1998 for a biological implant for bone repair that is now a market leading product. Prior to joining Osteotech, McBrayer held positions of increasing responsibility for Johnson & Johnson, Inc.

He has over 20 years healthcare senior management experience and served as an Infantry Officer Company Commander in the U.S. Army prior to beginning his business career. McBrayer is a graduate of the United States Military Academy at West Point.

About ACell, Inc.

ACell, Inc. is a leading regenerative medicine company focused on the development, manufacturing and commercialization of unique proprietary extracellular matrix (ECM) products to facilitate the repair and remodeling of damaged tissues. ACell is committed to becoming and remaining an innovative leader in regenerative medical technology, offering superior healing options for doctors and patients. ACell is a privately held company and operates manufacturing facilities in Columbia, MD and Lafayette, IN. For more information, call 800-826-2926 or visit

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

While the biotech IPO market booms, it can look like going public is easy. But the right strategy, syndicate and aftermarket are still important.

Gene therapy pioneer Jim Wilson and the University of Pennsylvania are teaming up with Regeneron to help deliver its COVID antibody intransally.

Forty percent of PK deficiency patients on mitapivat had hemoglobalin responses, compared to 0% in the placebo group.